Regeneron said Monday that it will comply with 23andMe's privacy policies and applicable law. (Scripps News) Maryland ...

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the July 18th expiration. One of the key data points that goes into the price an option ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...

Regeneron buying 23andMe ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.